Thiazolidinediones alter growth and epithelial cell integrity, independent of PPAR-γ and MAPK activation, in mouse M1 cortical collecting duct cells

被引:3
作者
Nasrallah, Rania [1 ]
Clark, Jordan [1 ]
Corinaldi, Jaime [1 ]
Paris, Genevieve [1 ]
Miura, Pedro [1 ]
Jasmin, Bernard J. [1 ]
Hebert, Richard L. [1 ]
机构
[1] Univ Ottawa, Fac Med, Kidney Res Ctr, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada
关键词
M1 collecting duct cells; troglitazone; rosiglitazone; PEROXISOME-PROLIFERATOR; RECEPTOR-GAMMA; BETA-CATENIN; EXPRESSION; MECHANISMS; SUPERFAMILY; ALPHA;
D O I
10.1152/ajprenal.00735.2009
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Nasrallah R, Clark J, Corinaldi J, Paris G, Miura P, Jasmin BJ, Hebert RL. Thiazolidinediones alter growth and epithelial cell integrity, independent of PPAR-gamma and MAPK activation, in mouse M1 cortical collecting duct cells. Am J Physiol Renal Physiol 298: F1105-F1112, 2010. First published February 17, 2010; doi:10.1152/ajprenal.00735.2009.-Peroxisome proliferator-activated receptor (PPAR)-gamma is highly expressed in the collecting duct (CD), yet little is known about the effects of PPAR-gamma ligands, thiazolidinediones (TZDs), on CD cell structure and function. M1 mouse cortical CD cells were treated with 5 mu M troglitazone (TRO) and rosiglitazone (ROSI). First, growth was measured by [H-3] thymidine and [H-3] leucine incorporation, as well as analysis of cyclin D1 and the CDK inhibitor p27 by Western blot. [H-3] thymidine incorporation was reduced by 56 and 24% by TRO and ROSI at 6 h, and [H-3] leucine by 21 and 10%. A similar growth inhibition was also observed after 24 h for thymidine, but leucine was reduced by 48 and 24%, respectively. Likewise, cyclin D1 was diminished 60% by TRO, and p27 was elevated 1.6- and 1.7-fold in response to TRO and ROSI. Next, epithelial cell integrity was assessed by measuring different markers by Western blot analysis. While fibronectin and alpha-smooth muscle actin levels were unchanged, by 24 h E-cadherin was decreased by 50%, and beta-catenin levels were reduced 2- and 1.5-fold in response to TRO and ROSI, respectively. GW9662, a PPAR-gamma antagonist, did not reverse any of the TZD responses in M1 cells. Of interest, phosho-p38 levels were also elevated 2- fold in response to TRO and 2.3-fold to ROSI, but MAPK inhibition by PD98059 or SB203580 caused an additive inhibition of cell growth and did not alter E-cadherin or beta-catenin in response to TZDs. Finally, apoptotic death was assessed by Western blot, but cleaved caspase-3 levels were unchanged from 15 min to 24 h in response to TZDs, and TRO did not affect cell viability or reactive oxygen species generation. Our data suggest that TZDs cause a disruption of M1 cell integrity that is preceded by an inhibition of cell growth. This response is independent of p38 or PPAR-gamma activation.
引用
收藏
页码:F1105 / F1112
页数:8
相关论文
共 40 条
  • [21] Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet
    Kume, Shinji
    Uzu, Takashi
    Araki, Shin-ichi
    Sugimoto, Toshiro
    Isshiki, Keiji
    Chin-Kanasaki, Masami
    Sakaguchi, Masayoshi
    Kubota, Naoto
    Terauchi, Yasuo
    Kadowaki, Takashi
    Haneda, Masakazu
    Kashiwagi, Atsunori
    Koya, Daisuke
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (10): : 2715 - 2723
  • [22] AN ANTIDIABETIC THIAZOLIDINEDIONE IS A HIGH-AFFINITY LIGAND FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA(PPAR-GAMMA)
    LEHMANN, JM
    MOORE, LB
    SMITHOLIVER, TA
    WILKISON, WO
    WILLSON, TM
    KLIEWER, SA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (22) : 12953 - 12956
  • [23] Functional interaction between peroxisome proliferator-activated receptor γ and β-catenin
    Liu, Jiajian
    Wang, Hong
    Zuo, Ying
    Farmer, Stephen R.
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (15) : 5827 - 5837
  • [24] THE NUCLEAR RECEPTOR SUPERFAMILY - THE 2ND DECADE
    MANGELSDORF, DJ
    THUMMEL, C
    BEATO, M
    HERRLICH, P
    SCHUTZ, G
    UMESONO, K
    BLUMBERG, B
    KASTNER, P
    MARK, M
    CHAMBON, P
    EVANS, RM
    [J]. CELL, 1995, 83 (06) : 835 - 839
  • [25] International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors
    Michalik, Liliane
    Auwerx, Johan
    Berger, Joel P.
    Chatterjee, V. Krishna
    Glass, Christopher K.
    Gonzalez, Frank J.
    Grimaldi, Paul A.
    Kadowaki, Takashi
    Lazar, Mitchell A.
    O'Rahilly, Stephen
    Palmer, Colin N. A.
    Plutzky, Jorge
    Reddy, Janardan K.
    Spiegelman, Bruce M.
    Staels, Bart
    Wahli, Walter
    [J]. PHARMACOLOGICAL REVIEWS, 2006, 58 (04) : 726 - 741
  • [26] The hypertrophic effect of transforming growth factor-β is reduced in the absence of cyclin-dependent kinase-inhibitors p21 and p27
    Monkawa, T
    Hiromura, K
    Wolf, G
    Shankland, SJ
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (05): : 1172 - 1178
  • [27] Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms
    Okada, Tatsuo
    Wada, Jun
    Hida, Kazuyuki
    Eguchi, Jun
    Hashimoto, Izumi
    Baba, Masako
    Yasuhara, Akihiro
    Shikata, Kenichi
    Makino, Hirofumi
    [J]. DIABETES, 2006, 55 (06) : 1666 - 1677
  • [28] Expression profile of genes regulated by activity of the Na-H exchanger NHE1
    Putney, LK
    Barber, DL
    [J]. BMC GENOMICS, 2004, 5 (1)
  • [29] Qin CH, 2003, CANCER RES, V63, P958
  • [30] Peroxisome proliferator-activated receptor γ activation can regulate β-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway
    Sharma, C
    Pradeep, A
    Wong, L
    Rana, A
    Rana, B
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (34) : 35583 - 35594